SCHEMBL2394322

SCHEMBL2394322

CCCCCC=COC=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.52
TRPV1 Q8NER1 2/20 0.52
TSHR P16473 2/20 0.48
ALDH1A1 P00352 1/20 0.48
LPAR3 Q9UBY5 1/20 0.41
TERT O14746 3/20 0.41
MAPT P10636 2/20 0.41
BLM P54132 2/20 0.41
HSD17B10 Q99714 2/20 0.41
FABP4 P15090 2/20 0.41
PTPN1 P18031 2/20 0.41
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10605584 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL8372060 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL4130341 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL2395653 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL3815755 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL3044334 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL6473139 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL6473135 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL3039634 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL4122077 0.98 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200121652-A1 COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT THE DOSHISHA (JP) 2020-04-23 US disclosed
EP-3639855-A1 COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT The Doshisha (JP) 2020-04-22 EP disclosed
US-9029572-B2 3-hydroxy-6H-benzo [C] chromene-6-one derivative and manufacturing method thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-05-12 US disclosed
US-8975256-B2 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-03-10 US disclosed
US-20140296540-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF AYUMI PHARMACEUTICAL CORPORATION (JP) 2014-10-02 US disclosed
US-8802869-B2 3-hydroxy-6H-benzo [c] chromene-6-one derivative and manufacturing method thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-12 US disclosed
EP-2674422-A1 3-HYDROXY-6H-BENZO[C]CHROMEN-6-ONE DERIVATIVE AND METHOD FOR PRODUCING SAME SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-12-18 EP disclosed
EP-1944290-B1 NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY SANTEN PHARMACEUTICAL CO LTD (JP) 2013-12-04 EP disclosed
US-20130310576-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-11-21 US disclosed
US-20130303537-A1 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-11-14 US disclosed
EP-1939198-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939199-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939200-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1316610-B1 Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same SUMITOMO CHEMICAL CO (JP) 2006-05-03 EP disclosed
US-6936445-B2 Enzyme preparation and method of using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-08-30 US disclosed
US-20030124683-A1 Enzyme preparation and method of using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-07-03 US disclosed
EP-1316610-A1 Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-04 EP disclosed
EP-0449049-B1 Naphthalenedicarboxylic acid esters HOFFMANN LA ROCHE (CH) 1994-12-28 EP disclosed
US-5230828-A NAPHTHALENEDICARBOXYLIC ACID ESTERS HOFFMANN-LA ROCHE INC. (US) 1993-07-27 US disclosed
EP-0449049-A2 Naphthalenedicarboxylic acid esters F. HOFFMANN-LA ROCHE AG (CH) 1991-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296540-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF CYP8B1, CTRC, CYP7B1 FAAH 2439/4885TRPV1 3229/4885TSHR 2795/4885
US-20130310576-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF CYP8B1, CTRC, CYP7B1 FAAH 2439/4885TRPV1 3229/4885TSHR 2795/4885
US-20200121652-A1 COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT TGFB1, CASP3, TGFB2 FAAH 1856/4885TRPV1 2942/4885TSHR 4706/4885
US-20130303537-A1 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY NR3C1, NR3C2, NR5A1 FAAH 3276/4885TRPV1 2340/4885TSHR 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.